{"id":5824,"date":"2025-08-21T07:19:05","date_gmt":"2025-08-21T07:19:05","guid":{"rendered":"https:\/\/oncopeptides.com\/investors\/aktien\/nyemissioner\/foretradesemission-2025\/"},"modified":"2026-03-18T15:53:09","modified_gmt":"2026-03-18T15:53:09","slug":"foretradesemission-2025","status":"publish","type":"investors","link":"https:\/\/oncopeptides.com\/sv\/investerare\/aktien\/nyemissioner\/foretradesemission-2025\/","title":{"rendered":"F\u00f6retr\u00e4desemission 2025"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"5824\" class=\"elementor elementor-5824 elementor-4201\" data-elementor-post-type=\"investors\">\n\t\t\t\t<style>\n                .elementor-element-64060d4{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-64060d4 e-flex e-con-boxed e-con e-parent\" data-id=\"64060d4\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<style>\n                .elementor-element-fa0cf6e{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-fa0cf6e e-con-full haus-2-1 e-flex e-con e-child\" data-id=\"fa0cf6e\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ebebb4a elementor-widget elementor-widget-heading\" data-id=\"ebebb4a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">F\u00f6retr\u00e4desemission<br><span style=\"color: var(--color-orange)\">2025<\/span><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a55afc9 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"a55afc9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-6aac97c{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-6aac97c e-con-full e-flex e-con e-child\" data-id=\"6aac97c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-bc74833 elementor-widget elementor-widget-text-editor\" data-id=\"bc74833\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides f\u00f6retr\u00e4desemission \u00f6vertecknad till cirka 157 procent<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-56766e8 elementor-widget elementor-widget-text-editor\" data-id=\"56766e8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>17 september 2025 \u2013 Regulatoriskt pressmeddelande \u2013 Oncopeptides AB (publ) offentligg\u00f6r utfallet i den fullt garanterade f\u00f6retr\u00e4desemissionen om cirka 150 miljoner kronor. Teckningsperioden f\u00f6r F\u00f6retr\u00e4desemissionen avslutades den 15 september 2025. Utfallet visar att 43 862 586 stamaktier, motsvarande cirka 93 procent av de erbjudna stamaktierna, har tecknats med st\u00f6d av teckningsr\u00e4tter i F\u00f6retr\u00e4desemissionen. D\u00e4rut\u00f6ver har anm\u00e4lningar om teckning av 29 834 852 stamaktier utan st\u00f6d av teckningsr\u00e4tter, motsvarande cirka 64 procent av de erbjudna stamaktierna, inkommit. F\u00f6retr\u00e4desemissionen \u00e4r d\u00e4rmed fulltecknad och inga garanti\u00e5taganden kommer att tas i anspr\u00e5k. F\u00f6retr\u00e4desemissionen kommer att tillf\u00f6ra Bolaget cirka 150 miljoner kronor f\u00f6re avdrag f\u00f6r transaktionskostnader relaterade till F\u00f6retr\u00e4desemissionen.<br>L\u00e4s hela pressreleasen     <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-04952e8 elementor-widget elementor-widget-button\" data-id=\"04952e8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-foretradesemission-overtecknad-till-cirka-157-procent\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c94903a dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"c94903a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-5408bf0{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-5408bf0 e-con-full e-flex e-con e-child\" data-id=\"5408bf0\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-057cd19 elementor-widget elementor-widget-heading\" data-id=\"057cd19\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Information f\u00f6r investerare<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-71d39a7 elementor-widget elementor-widget-text-editor\" data-id=\"71d39a7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Oncopeptides st\u00e4rker sin position p\u00e5 den europeiska cancerl\u00e4kemedelsmarknaden. Med l\u00e4kemedlet Pepaxti\u00ae, riktat mot patienter med multipelt myelom \u2013 en typ av blodcancer, har bolaget nu tre kvartal i rad levererat en f\u00f6rs\u00e4ljningstillv\u00e4xt p\u00e5 \u00f6ver 30 procent. F\u00f6r att accelerera expansionen och s\u00e4kra v\u00e4gen till l\u00f6nsamhet genomf\u00f6r bolaget en fullt garanterad nyemission om cirka 150 miljoner kronor med f\u00f6retr\u00e4desr\u00e4tt f\u00f6r bolagets befintliga aktie\u00e4gare.  <\/p><p>\u201dEmissionen ger oss finansiell flexibilitet att forts\u00e4tta v\u00e4xa i Europa och samtidigt utveckla v\u00e5r pipeline. Vi har en tydlig plan mot positivt kassafl\u00f6de i slutet av 2026, och emissionen s\u00e4kerst\u00e4ller att vi kan leverera p\u00e5 den planen \u2013 oavsett utfall i v\u00e5ra partnerdiskussioner i Japan\u201d, s\u00e4ger Oncopeptides vd Sofia Heigis.<\/p><p><strong>L\u00e4s fr\u00e5gor och svar f\u00f6r investerare, Informationsdokumentet, Anm\u00e4lningssedlar, pressmeddelanden, se Oncopeptalks, viktiga dokument och \u00f6vrig information nedan.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-77fe395 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"77fe395\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-a877543{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-a877543 e-con-full e-flex e-con e-child\" data-id=\"a877543\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c45c06b elementor-widget elementor-widget-heading\" data-id=\"c45c06b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Emissionen i korthet<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0434a72 elementor-widget elementor-widget-text-editor\" data-id=\"0434a72\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<ul><li>Teckningsperiod: 1\u201315 september 2025<\/li><li>Teckningskurs: 3,20 SEK per aktie<\/li><li>Villkor: Nio (9) teckningsr\u00e4tter ger r\u00e4tt att teckna tv\u00e5 (2) nya aktier<\/li><li>Utsp\u00e4dning: Cirka 18,2 % vid full teckning<\/li><li>Garanti: Emissionen \u00e4r fullt garanterad, med starkt st\u00f6d fr\u00e5n bland andra HealthCap, Schonfeld Global Master Fund och Maven Investment Partners<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-99e1105 elementor-widget elementor-widget-image\" data-id=\"99e1105\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<webien-image class=\" has-thumb ratio-original\">\r\n\t<img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/c1.webien.cloud\/pixel.webp\" width=\"2330\" height=\"547\" data-srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2025\/08\/sofia-heigis_img_5061_foto-liza-simonsson-hero-image.jpg\" data-original=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2025\/08\/sofia-heigis_img_5061_foto-liza-simonsson-hero-image.jpg\" data-optimize=\"1\" data-useoriginal=\"0\" data-ratio=\"none\" data-sizes=\"auto\" data-focus=\"attention\" class=\"main lazyload\" title=\"sofia-heigis_img_5061_foto-liza-simonsson-hero-image\" alt=\"\" \/>\r\n\t\r\n\t<img decoding=\"async\" width=\"2330\" height=\"547\" src=\"https:\/\/wrooom.webien.io\/eyJpbWFnZVVybCI6Imh0dHBzOi8vb25jb3BlcHRpZGVzLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNS8wOC9zb2ZpYS1oZWlnaXNfaW1nXzUwNjFfZm90by1saXphLXNpbW9uc3Nvbi1oZXJvLWltYWdlLmpwZyIsInB1YmxpY0tleSI6Im5vS2V5IiwiZWRpdHMiOnsicmVzaXplIjp7IndpZHRoIjoxNTAsImhlaWdodCI6MTUwLCJmaXQiOiJpbnNpZGUiLCJwb3NpdGlvbiI6ImF0dGVudGlvbiIsIndpdGhvdXRFbmxhcmdlbWVudCI6dHJ1ZX0sImJsdXIiOjEyfX0=\" class=\"thumb\" \/>\r\n\t<\/webien-image>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-687e74f{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-687e74f e-con-full e-flex e-con e-child\" data-id=\"687e74f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e241657 elementor-widget elementor-widget-heading\" data-id=\"e241657\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Prelimin\u00e4r tidsplan f\u00f6r F\u00f6retr\u00e4desemissionen<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0e6e6b2 elementor-widget elementor-widget-text-editor\" data-id=\"0e6e6b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<table width=\"614\"><tbody><tr><td width=\"454\">Sista dag f\u00f6r handel i aktien inklusive r\u00e4tt att erh\u00e5lla teckningsr\u00e4tter<\/td><td width=\"161\">26 augusti 2025<\/td><\/tr><tr><td width=\"161\"><\/td><td width=\"454\">F\u00f6rsta dag f\u00f6r handel i aktien exklusive r\u00e4tt att erh\u00e5lla teckningsr\u00e4tter<\/td>27 augusti 2025<\/tr><tr><td width=\"454\">Avst\u00e4mningsdag f\u00f6r r\u00e4tten att erh\u00e5lla teckningsr\u00e4tter<\/td><td width=\"161\">8 augusti 2025<\/td><\/tr><tr><td width=\"454\">Publicering av informationsdokument<\/td><td width=\"161\">28 augusti 2025<\/td><\/tr><tr><td width=\"161\"><\/td><td width=\"454\">Handel med teckningsr\u00e4tter<\/td>1 \u2013 10 september 2025<\/tr><tr><td width=\"454\">Teckningsperiod<\/td><td width=\"161\">1 \u2013 15 september 2025<\/td><\/tr><tr><td width=\"454\">Handel med BTA (Betald Tecknad Aktie)<\/td><td width=\"161\">1 \u2013 22 september 2025<\/td><\/tr><tr><td width=\"454\">Offentligg\u00f6rande av utfallet i F\u00f6retr\u00e4desemissionen<\/td><td width=\"161\">17 september 2025<\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5af4f02 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"5af4f02\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-43b1746{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-43b1746 e-con-full e-flex e-con e-child\" data-id=\"43b1746\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-efa5f29 elementor-widget elementor-widget-heading\" data-id=\"efa5f29\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Fr\u00e5gor och svar f\u00f6r investerare: F\u00f6retr\u00e4desemission och partnerskap i Japan<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-18fac2e elementor-widget elementor-widget-text-editor\" data-id=\"18fac2e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>\u00d6VERSIKT AV F\u00d6RETR\u00c4DESEMISSIONEN<\/h2>\n<p>Syftet \u00e4r att finansiera den p\u00e5g\u00e5ende kommersialiseringen av Pepaxti i Europa fram till dess att bolaget f\u00f6rv\u00e4ntas uppn\u00e5 ett positivt kassafl\u00f6de vid slutet av 2026, samt att s\u00e4kerst\u00e4lla tidig utveckling av bolagets portf\u00f6lj av prekliniska tillg\u00e5ngar.<\/p>\n<h3>1. Hur stor \u00e4r emissionen och hur \u00e4r den strukturerad?<\/h3>\n<p><strong>Svar:<\/strong> F\u00f6retr\u00e4desemissionen om 150 MSEK \u00e4r fullt garanterad med f\u00f6retr\u00e4desr\u00e4tt f\u00f6r befintliga aktie\u00e4gare. Den baseras p\u00e5 det bemyndigande som gavs vid \u00e5rsst\u00e4mman den 22 maj 2025 och \u00e4r utformad f\u00f6r att s\u00e4kra ytterligare finansiering f\u00f6r b\u00e5de kommersialisering av Pepaxti i Europa och tidig utveckling av prekliniska tillg\u00e5ngar. <\/p>\n<h3>2. Varf\u00f6r g\u00f6r Oncopeptides denna emission nu?<\/h3>\n<p><strong>Svar:<\/strong> Styrelsen anser att nettolikviden ger tillr\u00e4cklig finansiering f\u00f6r att n\u00e5 l\u00f6nsamhet och kassafl\u00f6despositivitet till fj\u00e4rde kvartalet 2026, oavsett utg\u00e5ngen av f\u00f6rhandlingarna om ett partnerskap i Japan. Det s\u00e4kerst\u00e4ller ocks\u00e5 finansiering f\u00f6r att driva bolagets pipeline fram\u00e5t, s\u00e4rskilt OPD5 och andra prekliniska projekt. <\/p>\n<h3>3. Hur bed\u00f6mer bolaget sin finansiella uth\u00e5llighet efter emissionen, och r\u00e4cker finansieringen hela v\u00e4gen till positivt kassafl\u00f6de 2026?<\/h3>\n<p><strong>Svar:<\/strong> Ja, emissionslikviden bed\u00f6ms av bolaget vara tillr\u00e4cklig f\u00f6r att n\u00e5 l\u00f6nsamhet och kassafl\u00f6despositivitet, oavsett om ett partnerskap i Japan uppn\u00e5s eller inte. Som kommunicerat kr\u00e4ver kassafl\u00f6despositivitet mot slutet av 2026 en f\u00f6rs\u00e4ljnings\u00f6kning p\u00e5 30-40 procent per kvartal. Vi utv\u00e4rderar kontinuerligt v\u00e5ra finansiella behov baserat p\u00e5 kommersiell utveckling, aff\u00e4rsutveckling och pipelineframskridande.  <\/p>\n<h3>4. Om ett partnerskap i Japan inte blir av eller f\u00f6rsenas, ser bolaget d\u00e5 behov av ytterligare finansiering p\u00e5 kort sikt?<\/h3>\n<p><strong>Svar:<\/strong> Som vid alla partnerskapsf\u00f6rhandlingar \u00e4r det sannolikt men inte s\u00e4kert att f\u00e5 en initial licensbetalning fr\u00e5n Japan innan ett avtal \u00e4r slutf\u00f6rt. Emissionslikviden bed\u00f6ms av styrelsen vara tillr\u00e4cklig f\u00f6r att n\u00e5 l\u00f6nsamhet och kassafl\u00f6despositivitet, oavsett utfallet av dessa f\u00f6rhandlingar. <\/p><p><br><\/p>\n<h2>VILLKOR OCH GENOMF\u00d6RANDE<\/h2>\n<h3>5. Vad \u00e4r teckningskursen och rabattniv\u00e5n?<\/h3>\n<p><strong>Svar:<\/strong> Teckningskursen \u00e4r 3,20 SEK per ny aktie, vilket motsvarar cirka 32 % rabatt j\u00e4mf\u00f6rt med den teoretiska ex-r\u00e4ttskursen (TERP) baserat p\u00e5 st\u00e4ngningskursen p\u00e5 Nasdaq Stockholm den 20 augusti 2025.<\/p>\n<h3>6. Hur m\u00e5nga nya aktier ges ut vid full teckning?<\/h3>\n<p><strong>Svar:<\/strong> Vid full teckning kommer 46\u202f947\u202f534 nya stamaktier att ges ut, vilket \u00f6kar aktiekapitalet med cirka 5\u202f216\u202f392,88 SEK och det totala antalet aktier fr\u00e5n 225\u202f758\u202f823 till 272\u202f706\u202f357.<\/p>\n<h3>7. Hur fungerar teckningsr\u00e4tterna?<\/h3>\n<p><strong>Svar:<\/strong><\/p>\n<ul>\n<li>Avst\u00e4mningsdag: 28 augusti 2025<\/li>\n<li>Varje aktie\u00e4gare den dagen f\u00e5r en teckningsr\u00e4tt per befintlig aktie<\/li>\n<li>Nio teckningsr\u00e4tter ger r\u00e4tt att teckna tv\u00e5 nya aktier<\/li>\n<li>Investerare kan \u00e4ven ans\u00f6ka om aktier utan teckningsr\u00e4tter genom en separat anm\u00e4lan<\/li>\n<\/ul>\n<h3>8. G\u00e5r det att s\u00e4lja eller k\u00f6pa teckningsr\u00e4tter?<\/h3>\n<p><strong>Svar:<\/strong> Ja, handel med teckningsr\u00e4tter kommer att ske p\u00e5 Nasdaq Stockholm mellan 1 och 15 september.<\/p><p><br><\/p>\n<p><\/p>\n<h2>ANV\u00c4NDNING AV EMMISIONSLIKVIDEN<\/h2>\n<h3>9. Vad anv\u00e4nds int\u00e4kterna fr\u00e5n nyemissionen fr\u00e4mst till?<\/h3>\n<p><strong>Svar:<\/strong><\/p>\n<ul>\n<li>Finansiera p\u00e5g\u00e5ende kommersialisering av Pepaxti\u00ae i Europa fram till ber\u00e4knad kassafl\u00f6despositivitet<\/li>\n<li>Driva prekliniska tillg\u00e5ngar fram\u00e5t, inklusive tidig utveckling av OPD5 mot IND-beredskap<\/li>\n<li>St\u00f6dja f\u00f6rs\u00e4ljningstillv\u00e4xt efter starkt Q2 och tidig marknadsintroduktion i Italien<\/li>\n<\/ul>\n<h3>10. Om ytterligare medel fr\u00e5n ett Japan-partnerskap erh\u00e5lls, f\u00f6r\u00e4ndrar det anv\u00e4ndningen av emissionslikviden?<\/h3>\n<p><strong>Svar:<\/strong> Om en f\u00f6rskottsbetalning i ett partnerskap i Japan erh\u00e5lls skulle medlen anv\u00e4ndas f\u00f6r att accelerera pipelineprojekt ut\u00f6ver vad som finansieras av denna emission.<\/p><p><br><\/p>\n<p><\/p>\n<h2>TECKNINGS\u00c5TAGANDEN OCH GARANTI\u00c5TAGANDEN<\/h2>\n<h3>11. Hur stor del av emissionen \u00e4r redan t\u00e4ckt?<\/h3>\n<p>100 % (ca 150 MSEK) \u00e4r t\u00e4ckt genom:<\/p>\n<ul>\n<li>HealthCap VIII LP har \u00e5tagit sig att teckna 15,5 miljoner SEK. Vissa styrelseledam\u00f6ter i Bolaget och ledande befattningshavare avser \u00e4ven att ing\u00e5 bindande teckningsf\u00f6rbindelser efter offentligg\u00f6randet av Bolagets del\u00e5rsrapport f\u00f6r det andra kvartalet 2025 upp till deras respektive pro rata-belopp och detta \u00e5tagande och dessa avsikter motsvarar cirka 11 procent av F\u00f6retr\u00e4desemissionen. <\/li>\n<li>Garanti\u00e5tanganden motsvarande 133.8 miljoner SEK.<\/li>\n<li>En fullst\u00e4ndig lista \u00f6ver \u00e5taganden kommer att publiceras den 28 augusti som en del av offentligg\u00f6randet av informationsdokumentet.<\/li>\n<\/ul>\n<h3>12. Deltar hela styrelsen och ledningen i nyemissionen?<\/h3>\n<p>En fullst\u00e4ndig lista \u00f6ver \u00e5taganden kommer att publiceras den 28 augusti som en del av informationsdokumentet.<\/p>\n<p>Ledande f\u00f6retr\u00e4dare f\u00f6r bolaget inklusive dess vd samt CFO har indikerat att de kommer att t\u00e4cka sin pro-rataandel som ett minumum.<\/p>\n<p>Att delta i en nyemission \u00e4r ett privatekonomiskt beslut och sk\u00e4l kan variera.<\/p>\n<h3>13. N\u00e4r aktiveras garanti\u00e5tagandena?<\/h3>\n<p>Garanten tecknar f\u00f6r eventuella ej tecknade aktier upp till 130 MSEK. <\/p><p><br><\/p>\n<h2>UTSP\u00c4DNING OCH LOCK-UP<\/h2>\n<h3>14. Vilken utsp\u00e4dning drabbar icke-deltagande aktie\u00e4gare?<\/h3>\n<p>Vid full teckning blir utsp\u00e4dningen 18,2 %. Aktie\u00e4gare kan minska utsp\u00e4dningen genom att s\u00e4lja sina teckningsr\u00e4tter. <\/p>\n<h3>15. Hur maximerar ni aktie\u00e4garv\u00e4rdet givet potentiell utsp\u00e4dning?<\/h3>\n<p>Genom att accelerera kommersiell tillv\u00e4xt i Europa, s\u00e4kra ett gynnsamt avtal i Japan och driva pipelineframsteg effektivt, vilket f\u00f6rv\u00e4ntas skapa l\u00e5ngsiktigt v\u00e4rde f\u00f6r alla aktie\u00e4gare.<\/p>\n<h3>16. Finns det lock-up-\u00e5taganden?<\/h3>\n<p>Ja.<\/p>\n<ul>\n<li>Styrelse och ledning har \u00e5tagit sig att inte f\u00f6resl\u00e5 nya emissioner eller s\u00e4lja aktier under 180 dagar efter offentligg\u00f6randet, med sedvanliga undantag..<\/li>\n<li>Bolaget kan dock emittera teckningsoptioner till Europeiska Investeringsbanken enligt tidigare avtal.<\/li>\n<\/ul><div><br><\/div>\n<h2>UPPDATERING ANG\u00c5ENDE POTENTIELLT PARTNERSKAP I JAPAN<\/h2>\n<h3>17. Vad \u00e4r status i f\u00f6rhandlingarna?<\/h3>\n<p>Bolaget \u00e4r f\u00f6r n\u00e4rvarande i framskridna diskussioner med en mycket v\u00e4lrenommerad partner, med due diligence-processen i ett sent skede, baserat p\u00e5 ett icke-bindande erbjudande som \u00e4r i linje med marknadspraxis och som inkluderar flera betydande f\u00f6rskottsbetalningar f\u00f6rskotts- och milstolpesbetalningar samt en tv\u00e5siffrig royalty, d\u00e4r partnern st\u00e5r f\u00f6r alla kostnader relaterade till regulatoriska aktiviteter och kommersialisering i Japan. Bolaget har d\u00e4rtill \u00e4ven mottagit ett icke-bindande erbjudande fr\u00e5n en annan potentiell partner som Bolaget \u00f6verv\u00e4ger parallellt.<\/p>\n<h3>18. F\u00f6rv\u00e4ntade kommersiella villkor i ett Japan-avtal<\/h3>\n<ul>\n<li>Partnern tar alla kostnader f\u00f6r regulatoriska aktiviteter och kommersialisering i Japan.<\/li>\n<li>Initial betalning, milstolpsbetalningar vid kliniska och kommersiella framsteg samt tv\u00e5siffrig stegvis royalty p\u00e5 nettof\u00f6rs\u00e4ljning.<\/li>\n<\/ul><div><br><\/div>\n<h2>RISKER OCH FRAM\u00c5TBLICKANDE UTTALANDEN<\/h2>\n<h3>19. Vilken ansvarsfriskrivning g\u00e4ller f\u00f6r fram\u00e5tblickande uttalanden?<\/h3>\n<p>Detta dokument inneh\u00e5ller fram\u00e5tblickande uttalanden och prognoser som inneb\u00e4r k\u00e4nda och ok\u00e4nda risker. Faktiska resultat kan skilja sig v\u00e4sentligt. Investerare b\u00f6r l\u00e4sa det fullst\u00e4ndiga informationsdokumentet enligt Prospektf\u00f6rordningen f\u00f6r detaljerad riskanalys.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7a282a7 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"7a282a7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-4108842{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-4108842 e-con-full e-flex e-con e-child\" data-id=\"4108842\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9350c4f elementor-widget elementor-widget-text-editor\" data-id=\"9350c4f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>DENNA INFORMATION F\u00c5R INTE OFFENTLIGG\u00d6RAS, PUBLICERAS ELLER DISTRIBUERAS, DIREKT ELLER INDIREKT, I ELLER TILL AUSTRALIEN, HONGKONG, ISRAEL, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, USA ELLER N\u00c5GON ANNAN JURISDIKTION D\u00c4R S\u00c5DAN \u00c5TG\u00c4RD HELT ELLER DELVIS \u00c4R F\u00d6REM\u00c5L F\u00d6R LEGALA RESTRIKTIONER. DENNA INFORMATION UTG\u00d6R INTE ETT ERBJUDANDE ATT F\u00d6RV\u00c4RVA V\u00c4RDEPAPPER I ONCOPEPTIDES AB (PUBL). <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7368baf dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"7368baf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a0476b0 elementor-widget elementor-widget-spacer\" data-id=\"a0476b0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-e9894a1{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-e9894a1 e-con-full e-flex e-con e-child\" data-id=\"e9894a1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b18cef5 elementor-widget elementor-widget-heading\" data-id=\"b18cef5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Oncopeptalks om Emissionen, Europa och IMS<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b50a924 elementor-widget elementor-widget-image\" data-id=\"b50a924\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<webien-image class=\" has-thumb ratio-original\">\r\n\t<img decoding=\"async\" src=\"https:\/\/c1.webien.cloud\/pixel.webp\" width=\"1920\" height=\"1080\" data-srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/01\/2057803807-a42002c18bd948aa3b62be8e6448329988d73494c8b0dd0631e13b470414e98b-d_1920x1080.jpeg\" data-original=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/01\/2057803807-a42002c18bd948aa3b62be8e6448329988d73494c8b0dd0631e13b470414e98b-d_1920x1080.jpeg\" data-optimize=\"1\" data-useoriginal=\"0\" data-ratio=\"none\" data-sizes=\"auto\" data-focus=\"attention\" class=\"main lazyload\" title=\"2025-09-11_1920x1080\" alt=\"\" \/>\r\n\t\r\n\t<img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"1080\" src=\"https:\/\/wrooom.webien.io\/eyJpbWFnZVVybCI6Imh0dHBzOi8vb25jb3BlcHRpZGVzLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNi8wMS8yMDU3ODAzODA3LWE0MjAwMmMxOGJkOTQ4YWEzYjYyYmU4ZTY0NDgzMjk5ODhkNzM0OTRjOGIwZGQwNjMxZTEzYjQ3MDQxNGU5OGItZF8xOTIweDEwODAuanBlZyIsInB1YmxpY0tleSI6Im5vS2V5IiwiZWRpdHMiOnsicmVzaXplIjp7IndpZHRoIjoxNTAsImhlaWdodCI6MTUwLCJmaXQiOiJpbnNpZGUiLCJwb3NpdGlvbiI6ImF0dGVudGlvbiIsIndpdGhvdXRFbmxhcmdlbWVudCI6dHJ1ZX0sImJsdXIiOjEyfX0=\" class=\"thumb\" \/>\r\n\t<\/webien-image>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-93378b5 elementor-widget elementor-widget-text-editor\" data-id=\"93378b5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>11 september 2025 &#8211; I det senaste avsnittet av Oncopeptalks diskuterar David och Sofia den p\u00e5g\u00e5ende f\u00f6retr\u00e4desemissionen, den europeiska marknaden och IMS i Toronto, Kanada.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e03fd5f elementor-widget elementor-widget-button\" data-id=\"e03fd5f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/oncopeptalks\/oncopeptalks-om-emissionen-europa-och-ims\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Se avsnittet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f9a5ef2 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"f9a5ef2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f084eba elementor-widget elementor-widget-spacer\" data-id=\"f084eba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-eadfe60{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-eadfe60 e-con-full e-flex e-con e-child\" data-id=\"eadfe60\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-35248f8 elementor-widget elementor-widget-heading\" data-id=\"35248f8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Information om anm\u00e4lningssedlarna<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ca1c486 elementor-widget elementor-widget-text-editor\" data-id=\"ca1c486\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>V\u00e4nligen notera att anm\u00e4lningssedlarna nedan \u00e4r f\u00f6r direkt\u00e4gande aktie\u00e4gare. \u00c4ger du aktier via din bank, exempelvis Avanza eller Nordnet, kommer du att kunna teckna dig den v\u00e4gen. Teckningsr\u00e4tter f\u00f6r nuvarande aktie\u00e4gare kommer att distribueras den 1 september.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-47c81b2{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-47c81b2 e-con-full e-flex e-con e-child\" data-id=\"47c81b2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-322110c elementor-widget elementor-widget-heading\" data-id=\"322110c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Dokument till f\u00f6retr\u00e4desemissionen<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e4be756 elementor-position-inline-end elementor-view-default elementor-widget elementor-widget-icon-box\" data-id=\"e4be756\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-box.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-box-wrapper\">\n\n\t\t\t\t\t\t<div class=\"elementor-icon-box-icon\">\n\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-informationsdokument-in-swedish.pdf\" target=\"_blank\" class=\"elementor-icon\" tabindex=\"-1\" aria-label=\"Informationsdokument - F\u00f6retr\u00e4desemission 2025\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"onco onco-Download-3\"><\/i>\t\t\t\t<\/a>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t<div class=\"elementor-icon-box-content\">\n\n\t\t\t\t\t\t\t\t\t<h3 class=\"elementor-icon-box-title\">\n\t\t\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-informationsdokument-in-swedish.pdf\" target=\"_blank\" >\n\t\t\t\t\t\t\tInformationsdokument - F\u00f6retr\u00e4desemission 2025\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<p class=\"elementor-icon-box-description\">\n\t\t\t\t\t\tpdf, 110 KB\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-54a0058 elementor-position-inline-end elementor-view-default elementor-widget elementor-widget-icon-box\" data-id=\"54a0058\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-box.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-box-wrapper\">\n\n\t\t\t\t\t\t<div class=\"elementor-icon-box-icon\">\n\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-anmalningssedel-med-foretradesratt-eng-2025.pdf\" target=\"_blank\" class=\"elementor-icon\" tabindex=\"-1\" aria-label=\"Oncopeptides anm\u00e4lningssedel - Med F\u00f6retr\u00e4desr\u00e4tt\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"onco onco-Download-3\"><\/i>\t\t\t\t<\/a>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t<div class=\"elementor-icon-box-content\">\n\n\t\t\t\t\t\t\t\t\t<h3 class=\"elementor-icon-box-title\">\n\t\t\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-anmalningssedel-med-foretradesratt-eng-2025.pdf\" target=\"_blank\" >\n\t\t\t\t\t\t\tOncopeptides anm\u00e4lningssedel - Med F\u00f6retr\u00e4desr\u00e4tt\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<p class=\"elementor-icon-box-description\">\n\t\t\t\t\t\tpdf, 358 KB\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9088e83 elementor-position-inline-end elementor-view-default elementor-widget elementor-widget-icon-box\" data-id=\"9088e83\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-box.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-box-wrapper\">\n\n\t\t\t\t\t\t<div class=\"elementor-icon-box-icon\">\n\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-anmalningssedel-utan-foretradesratt-eng-2025.pdf\" target=\"_blank\" class=\"elementor-icon\" tabindex=\"-1\" aria-label=\"Oncopeptides anm\u00e4lningssedel - Utan F\u00f6retr\u00e4desr\u00e4tt\">\n\t\t\t\t<i aria-hidden=\"true\" class=\"onco onco-Download-3\"><\/i>\t\t\t\t<\/a>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t<div class=\"elementor-icon-box-content\">\n\n\t\t\t\t\t\t\t\t\t<h3 class=\"elementor-icon-box-title\">\n\t\t\t\t\t\t<a href=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/oncopeptides-anmalningssedel-utan-foretradesratt-eng-2025.pdf\" target=\"_blank\" >\n\t\t\t\t\t\t\tOncopeptides anm\u00e4lningssedel - Utan F\u00f6retr\u00e4desr\u00e4tt\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<p class=\"elementor-icon-box-description\">\n\t\t\t\t\t\tpdf, 370 KB\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cb6c494 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"cb6c494\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2e25f5d elementor-widget elementor-widget-spacer\" data-id=\"2e25f5d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-9fbbb13{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-9fbbb13 e-con-full e-flex e-con e-child\" data-id=\"9fbbb13\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5bc8bca elementor-widget elementor-widget-heading\" data-id=\"5bc8bca\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Vd Sofia Heigis i intervju med Biostock<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-68c63e3 elementor-widget elementor-widget-image\" data-id=\"68c63e3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"720\" src=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2025\/08\/sofia-heigis-at-biostock.webp\" class=\"attachment-full size-full wp-image-5822\" alt=\"\" sizes=\"(max-width: 1280px) 100vw, 1280px\" srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2025\/08\/sofia-heigis-at-biostock.webp 1280w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2025\/08\/sofia-heigis-at-biostock-300x169.webp 300w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2025\/08\/sofia-heigis-at-biostock-1024x576.webp 1024w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2025\/08\/sofia-heigis-at-biostock-768x432.webp 768w\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7ed7ecb elementor-widget elementor-widget-text-editor\" data-id=\"7ed7ecb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Oncopeptides befinner sig i en expansiv fas med fortsatt tillv\u00e4xt f\u00f6r Pepaxti p\u00e5 den europeiska marknaden och framsteg i de internationella satsningarna. Vd Sofia Heigis ber\u00e4ttar i en intervju med BioStock om bolagets l\u00e5ngsiktiga vision, den kommersiella utvecklingen och de p\u00e5g\u00e5ende f\u00f6rhandlingarna i Japan. Hon kommenterar \u00e4ven den aktuella f\u00f6retr\u00e4desemissionen och f\u00f6rklarar varf\u00f6r Oncopeptides anser sig vara en attraktiv investering just nu.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-21a282e elementor-widget elementor-widget-button\" data-id=\"21a282e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/biostock.se\/2025\/09\/oncopeptides-vi-ar-i-en-enorm-tillvaxtfas\/\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Se intervjun h\u00e4r<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7b9ef4c dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"7b9ef4c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-b1c4540{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-b1c4540 e-con-full e-flex e-con e-child\" data-id=\"b1c4540\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-95b3e83 elementor-widget elementor-widget-text-editor\" data-id=\"95b3e83\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Pressmeddelande<\/p><h2>Oncopeptides offentligg\u00f6r informationsdokument avseende f\u00f6retr\u00e4desemission<\/h2><p>28 augusti 2025 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB (publ) (\u201dOncopeptides\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: ONCO) offentligg\u00f6r informationsdokument avseende Bolagets nyemission med f\u00f6retr\u00e4desr\u00e4tt f\u00f6r befintliga aktie\u00e4gare om cirka 150 MSEK, som beslutades av styrelsen den 21 augusti 2025 med st\u00f6d av bemyndigande fr\u00e5n \u00e5rsst\u00e4mman den 22 maj 2025 (\u201dF\u00f6retr\u00e4desemissionen\u201d). Informationsdokumentet har registrerats hos Finansinspektionen och finns tillg\u00e4ngligt p\u00e5 Bolagets webbplats. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-681b44f elementor-widget elementor-widget-button\" data-id=\"681b44f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-offentliggor-informationsdokument-avseende-foretradesemission\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s mer<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bffff06 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"bffff06\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4894ce1 elementor-widget elementor-widget-spacer\" data-id=\"4894ce1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-26a2242{\n                --padding-top: var(--webien-padding-top-default);\n                --padding-right: var(--webien-padding-right-default);\n                --padding-bottom: var(--webien-padding-bottom-default);\n                --padding-left: var(--webien-padding-left-default);\n                }\n            <\/style><div class=\"webien-container-padding-default elementor-element elementor-element-26a2242 e-con-full e-flex e-con e-child\" data-id=\"26a2242\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<style>\n                .elementor-element-a6bf838{\n                --padding-top: var(--webien-padding-top-default);\n                --padding-right: var(--webien-padding-right-default);\n                --padding-bottom: var(--webien-padding-bottom-default);\n                --padding-left: var(--webien-padding-left-default);\n                }\n            <\/style><div class=\"webien-container-padding-default elementor-element elementor-element-a6bf838 e-con-full e-flex e-con e-child\" data-id=\"a6bf838\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-aa6170e elementor-widget elementor-widget-image\" data-id=\"aa6170e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<webien-image class=\" has-thumb ratio-original\">\r\n\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/c1.webien.cloud\/pixel.webp\" width=\"1919\" height=\"1079\" data-srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2025\/08\/ceo-sofia-heigis-interviewed-by-redeye.png\" data-original=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2025\/08\/ceo-sofia-heigis-interviewed-by-redeye.png\" data-optimize=\"1\" data-useoriginal=\"0\" data-ratio=\"none\" data-sizes=\"auto\" data-focus=\"attention\" class=\"main lazyload\" title=\"Vd Sofia Heigis intervjuad av Redeye\" alt=\"\" \/>\r\n\t\r\n\t<img loading=\"lazy\" decoding=\"async\" width=\"1919\" height=\"1079\" src=\"https:\/\/wrooom.webien.io\/eyJpbWFnZVVybCI6Imh0dHBzOi8vb25jb3BlcHRpZGVzLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNS8wOC9jZW8tc29maWEtaGVpZ2lzLWludGVydmlld2VkLWJ5LXJlZGV5ZS5wbmciLCJwdWJsaWNLZXkiOiJub0tleSIsImVkaXRzIjp7InJlc2l6ZSI6eyJ3aWR0aCI6MTUwLCJoZWlnaHQiOjE1MCwiZml0IjoiaW5zaWRlIiwicG9zaXRpb24iOiJhdHRlbnRpb24iLCJ3aXRob3V0RW5sYXJnZW1lbnQiOnRydWV9LCJibHVyIjozfX0=\" class=\"thumb\" \/>\r\n\t<\/webien-image>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-7b54a8c{\n                --padding-top: var(--webien-padding-top-default);\n                --padding-right: var(--webien-padding-right-default);\n                --padding-bottom: var(--webien-padding-bottom-default);\n                --padding-left: var(--webien-padding-left-default);\n                }\n            <\/style><div class=\"webien-container-padding-default elementor-element elementor-element-7b54a8c e-con-full e-flex e-con e-child\" data-id=\"7b54a8c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<style>\n                .elementor-element-2d3cbc2{\n                --padding-top: var(--webien-padding-top-default);\n                --padding-right: var(--webien-padding-right-default);\n                --padding-bottom: var(--webien-padding-bottom-default);\n                --padding-left: var(--webien-padding-left-default);\n                }\n            <\/style><div class=\"webien-container-padding-default elementor-element elementor-element-2d3cbc2 e-con-full e-flex e-con e-child\" data-id=\"2d3cbc2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1dc7fcd elementor-widget elementor-widget-heading\" data-id=\"1dc7fcd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Vd Sofia Heigis intervjuad av Redeye<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-95cc6d0 elementor-widget elementor-widget-text-editor\" data-id=\"95cc6d0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>25 augusti 2025 \u2013 Redeyes analytiker Richard Ramanius intervjuar Sofia med anledning av den andra kvartalsrapporten 2025 och f\u00f6retr\u00e4desemissionen.<\/p><p> <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-76812e3{\n                --padding-top: var(--webien-padding-top-default);\n                --padding-right: var(--webien-padding-right-default);\n                --padding-bottom: var(--webien-padding-bottom-default);\n                --padding-left: var(--webien-padding-left-default);\n                }\n            <\/style><div class=\"webien-container-padding-default elementor-element elementor-element-76812e3 e-con-full e-flex e-con e-child\" data-id=\"76812e3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c54c883 elementor-widget elementor-widget-button\" data-id=\"c54c883\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.redeye.se\/research\/1124349\/oncopeptides-q225-intervju-med-vd-sofia-heigis\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Se intervjun h\u00e4r<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-be784b0 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"be784b0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-68ed6ae{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-68ed6ae e-con-full e-flex e-con e-child\" data-id=\"68ed6ae\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6e88673 elementor-widget elementor-widget-text-editor\" data-id=\"6e88673\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Pressmeddelande<\/p><h2>Oncopeptides ing\u00e5r ytterligare garanti\u00e5taganden, f\u00f6retr\u00e4desemissionen fullt garanterad<\/h2><p>25 augusti 2025 \u2013 Regulatoriskt pressmeddelande<\/p><p>Den 21 augusti 2025 beslutade styrelsen i Oncopeptides AB (publ) med st\u00f6d av bemyndigandet fr\u00e5n \u00e5rsst\u00e4mman 22 maj 2025, att genomf\u00f6ra en f\u00f6retr\u00e4desemission om cirka 150 MSEK. F\u00f6retr\u00e4desemissionen var vid denna tidpunkt s\u00e4kerst\u00e4lld genom teckningsf\u00f6rbindelser, teckningsavsikter och garanti\u00e5taganden till cirka 87 procent, motsvarande 130 MSEK. Bolaget har nu erh\u00e5llit ytterligare garanti\u00e5taganden om cirka 20 MSEK, vilket inneb\u00e4r att teckningsf\u00f6rbindelser och garanti\u00e5taganden nu uppg\u00e5r till 100 procent av F\u00f6retr\u00e4desemissionen. De Nya Garanti\u00e5tagandena \u00e4r s\u00e5 kallad toppgarantier.   <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6320a2b elementor-widget elementor-widget-button\" data-id=\"6320a2b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ingar-ytterligare-garantiataganden-foretradesemissionen-fullt-garanterad\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s mer<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-77cb2cf dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"77cb2cf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e23f8c8 elementor-widget elementor-widget-spacer\" data-id=\"e23f8c8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-3c851b2{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-3c851b2 e-con-full e-flex e-con e-child\" data-id=\"3c851b2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-611c23a elementor-widget elementor-widget-text-editor\" data-id=\"611c23a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Pressmeddelande<\/p><h2>Oncopeptides genomf\u00f6r f\u00f6retr\u00e4desemission om cirka 150 MSEK och ger en uppdatering om det potentiella partnerskapet i Japan<\/h2><p>21 augusti 2025 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB (publ) meddelar h\u00e4rmed att styrelsen har beslutat att genomf\u00f6ra en delvis garanterad nyemission om cirka 150 MSEK med f\u00f6retr\u00e4desr\u00e4tt f\u00f6r Bolagets befintliga aktie\u00e4gare med st\u00f6d av bemyndigandet som beviljades av \u00e5rsst\u00e4mman den 22 maj 2025. Syftet med F\u00f6retr\u00e4desemissionen \u00e4r att finansiera den p\u00e5g\u00e5ende kommersialiseringen av Pepaxti\u00ae i Europa fram till dess att Bolaget f\u00f6rv\u00e4ntas uppn\u00e5 ett positivt kassafl\u00f6de vid utg\u00e5ngen av 2026, samt att s\u00e4kerst\u00e4lla tidig utveckling av Bolagets portf\u00f6lj av prekliniska tillg\u00e5ngar. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a68c20f elementor-widget elementor-widget-button\" data-id=\"a68c20f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-genomfor-foretradesemission-om-cirka-150-msek-och-ger-en-uppdatering-om-det-potentiella-partnerskapet-i-japan\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s mer<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8f4d1ad dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"8f4d1ad\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1550ae2 elementor-widget elementor-widget-spacer\" data-id=\"1550ae2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":0,"parent":5698,"menu_order":0,"template":"","meta":{"_acf_changed":false},"protected-content":[341],"class_list":["post-5824","investors","type-investors","status-publish","hentry","protected-content-show-disclaimer"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/investors"}],"version-history":[{"count":5,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5824\/revisions"}],"predecessor-version":[{"id":6815,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5824\/revisions\/6815"}],"up":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5698"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=5824"}],"wp:term":[{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/protected-content?post=5824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}